Huazhong University of Science and Technology Details Findings in Cancer Gene Therapy (KAP-1 is overexpressed and correlates with increased metastatic ability and tumorigenicity in pancreatic cancer)
By a News Reporter-Staff News Editor at Cancer Gene Therapy Week -- Data detailed on Biotechnology have been presented. According to news reporting from Hubei, People's Republic of China, by NewsRx journalists, research stated, "This study aimed to investigate the role in metastasis and prognostic value of KAP-1 in pancreatic cancer (PC). The expression of KAP-1 was analyzed by quantitative real-time polymerase chain reaction, Western blotting, and immunohistochemical staining in 91 human PC tissue samples."
The news correspondents obtained a quote from the research from the Huazhong University of Science and Technology, "Capan-2 cells were transfected with a lentiviral vector expressing KAP-1 (Capan-2/KAP-1) or the empty vector (Capan-2/vector); cell migration and invasion were assayed in vitro using Transwell migration and wound-healing assays, and in vivo using a xenograft model in nude mice. KAP-1 was found to be overexpressed in human PC, and the expression of KAP-1 correlated with clinical stage. Overexpression of KAP-1 increased the invasion and migration of Capan-2 cells in vitro. Furthermore, overexpression of KAP-1 promoted the growth and metastatic ability of PC cells in a xenograft model in nude mice. Moreover, overexpression of KAP-1 induced the epithelial-mesenchymal transition (EMT) in PC cells both in vitro and in vivo, as indicated by increased expression of mesenchymal markers such as vimentin and decreased expression of E-cadherin."
According to the news reporters, the research concluded: "This study indicates that KAP-1 may promote metastasis in PC by regulating the EMT and suggests that KAP-1 may have potential as a predictor of metastasis in patients with pancreatic cancer."
For more information on this research see: KAP-1 is overexpressed and correlates with increased metastatic ability and tumorigenicity in pancreatic cancer. Medical Oncology, 2014;31(7):157-165. Medical Oncology can be contacted at: Humana Press Inc, 999 Riverview Drive Suite 208, Totowa, NJ 07512, USA. (Springer - www.springer.com; Medical Oncology - www.springerlink.com/content/1357-0560/)
Our news journalists report that additional information may be obtained by contacting C. Yu, Huazhong University of Science & Technology, Affiliated Tongji Hosp, Dept. of Biliary Pancreat Surg, Tongji Med College, Wuhan 430030, Hubei, People's Republic of China. Additional authors for this research include L. Zhan, J.X. Jiang, Y.Z. Pan, H. Zhang, X. Li, F. Pen, M. Wang, R.Y. Qin and C.Y. Sun (see also Biotechnology).
Keywords for this news article include: Asia, Biotechnology, Hubei, Oncology, Xenograft, Gastroenterology, Pancreatic Cancer, Xenotransplantion, Cancer Gene Therapy, Pancreatic Neoplasms, People's Republic of China
Our reports deliver fact-based news of research and discoveries from around the world. Copyright 2014, NewsRx LLC